{"id":"W2790684790","doi":"10.1111/jdv.14913","title":"Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials","year":2018,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":37,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Valeant Pharmaceuticals International","keywords":"Medicine; Ustekinumab; Psoriasis; Randomized controlled trial; Placebo; Visual analogue scale; Dermatology Life Quality Index; Ixekizumab; Internal medicine; Dermatology; Physical therapy; Secukinumab; Adalimumab; Psoriatic arthritis; Disease","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004358664,0.0002288385,0.002776471,0.0003564891,0.00007408109,0.000005231668,0.0002519603,0.0002567165,0.00005857325],"category_scores_gemma":[0.0006225795,0.0001156804,0.0002536575,0.0001282254,0.001108311,0.00006122475,0.00008945713,0.0003851354,0.000005693963],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001583619,"about_ca_system_score_gemma":0.00004435197,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001302528,"about_ca_topic_score_gemma":0.0000170539,"domain_scores_codex":[0.990732,0.007116195,0.00163096,0.0001977622,0.00004662495,0.0002765184],"domain_scores_gemma":[0.9967732,0.001506926,0.001539813,0.0001067334,0.00004390165,0.00002935867],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.570236,0.001203646,0.2801884,0.00008685848,0.007213174,0.0001921229,0.003234096,0.000007328867,0.07123753,0.005667152,0.000615613,0.06011804],"study_design_scores_gemma":[0.9298802,0.0004581882,0.02238765,0.0002577088,0.001672868,0.004914285,0.0002109384,0.00001740668,0.03565927,0.001387527,0.002893122,0.0002608029],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9884991,0.007628353,0.00002962911,0.002073489,0.0003910969,0.0005382554,0.000007139427,0.000004739967,0.0008281889],"genre_scores_gemma":[0.9985704,0.0006643209,0.00006229163,0.0004560632,0.00008830901,0.00001167981,8.062742e-7,0.00001526006,0.0001308823],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3596442,"threshold_uncertainty_score":0.471731,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02023143258453447,"score_gpt":0.2847596844312664,"score_spread":0.2645282518467319,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}